European regulators have given the thumbs-up to Bayer's Jaydess, a low-dose controlled-release hormonal contraceptive.
When Bayer agreed to buy U.S.-based vitamin-and-OTC drug maker Schiff ($SHF), the company's reasoning went something like this: Let's supplement our risky pharma business with some steady, reliable, low-risk revenue. It's less profitable and less sexy, but sometimes, less can be more.
With the steady (and very loud) drumbeat of bad news this year about the patent cliff's toll on pharma sales and earnings, investing in the industry hasn't been a nonstop party. Still, the sector has outperformed major indices, and some stellar players have emerged. Of course, huge disappointments have cropped up, too. Read the report >>
Bayer and partner Regeneron have notched another win for Eylea, getting approval for the eye drug in Europe for treating wet age-related macular degeneration.
Rack up another set of new uses for Bayer's Xarelto. The anticoagulant won European approval to treat and prevent pulmonary embolism and to prevent deep vein thrombosis. It's the first warfarin-alternative drug to win these indications, giving it an edge over its rival Pradaxa.
If you were looking for a bidding war over Schiff Nutrition to give your Thanksgiving feast an ironic twist, you're going to be disappointed. Bayer says it's patently not interested in trumping Reckitt Benckiser's $1.4 billion offer.
The aggressive diversification campaign of Bayer CEO Marijn Dekkers has been checked, at least temporarily, by Reckitt Benckiser Group, which has moved on Schiff Nutrition International with a bid of its own.
While other drugmakers cut prices, set up access plans or wrangle with the Chinese government to sell products in that country, Roche ($RHHBY) is taking a more indirect tack. As Bloomberg reports, the Swiss drugmaker has teamed up with the reinsurer Swiss Re to sell private insurance to middle-class Chinese. That way, more patients can afford to use the company's pricey cancer drugs.
Bayer Healthcare is on a roll, and it has no intention of easing off the gas now. Emboldened by rising sales of Xarelto, pumped by the prospects of the macular degeneration drug Eylea and optimistic about the newly approved cancer drug Stivarga, Bayer's pharma division has outlined some ambitious plans for its $4 billion annual R&D budget.
Bayer HealthCare has struck a deal with a Russian drug manufacturer that will allow it to start producing products in a country that is considered one of the best bets for future growth.